CARMA Therapeutics, a company that develops chimeric antigen receptor technology, not for T-cells (CAR-T cells), rather, for macrophages, hence the name “CARMA,” closed on an initial round of funding to advance its technologies. Continue reading
Tag Archives: TAM
Cancer-Associated Macrophage-Like Cells (CAML) – Liquid Biopsy for Cancer Diagnosis, Prognosis, Staging, and Monitoring
Cancers are tumors that cross the basement membrane and develop invasiveness, the ability to intravasate into blood vessels, and then to colonize and grow at distant sites. Complex heterotypic cellular interactions inside the tumor are responsible for this.